Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: A meta-analysis and systematic review of published studies

Journal of Cardiovascular Medicine

Volumn 15, Issue 12, 2014, Pages 864-872

  Zhuang, Jianhui ^a   Faggiano, Pompilio ^b   Li, Qi ^c   Pradelli, Danitza ^e   Med, Vet ^d   Peng, Wenhui ^a   Zuo, Mei ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Nose and Throat   (China)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e NONE

Author keywords

Carbohydrate antigen 125; Heart failure; Meta analysis; Systematic review

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN 125; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ECHOCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HUMAN; META ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PLEURA EFFUSION; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BLOOD; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; HEART FAILURE; HUMANS; MEMBRANE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84916603411     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000051     Document Type: Review

References (34)

1. Hunt SA, Abraham WT, Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391-e479.
2. Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 2011; 58:1890-1892.
3. Faggiano P, D'Aloia A, Brentana L, et al Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005; 7:57-61.
4. Varol E, Ozaydin M, Dogan A., Kosar F. Tumour marker levelsin patients with chronic heart failure. Eur J Heart Fail 2005; 7:840-843.
5. Stroup DF, Berlin JA, Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
6. Dickstein K, Cohen-Solal A, Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
7. Wells G, Tugwell P, Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23:529-539.
8. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5:13.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
10. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
11. Nunez J, Nunez E, Consuegra L., et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 2007; 93:716-721.
12. Nunez J, Sanchis J, Bodi V., et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010; 31:1752-1763.
13. Chen YX, Wang XQ, Fang C.F., et al. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol 2008; 63:501-506.
14. D'Aloia A., Faggiano P, Aurigemma G., et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41:1805-1811.
15. Vizzardi E, Nodari S, D'Aloia A, et al. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography 2008; 25:955-960.
16. Mansour IN, Napan S, Tarek Alahdab M, Stamos TD. Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 2009; 16:15-20.
17. Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 2011; 149:80-82.
18. Nagele H, Bahlo M, Klapdor R., et al. CA 125 and its relation to cardiac function. Am Heart J 1999; 137:1044-1049.
19. Kouris NT, Kontogianni DD, Papoulia E.P., et al. Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure. Hellenic J Cardiol 2006; 47:269-274.
20. Monteiro S, Franco F, Costa S., et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 2009; 140:115-118.
21. Antonini-Canterin F., Popescu BA, Popescu A.C., et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 2008; 128:406-412.
22. Duman C, Ercan E, Tengiz I., et al. Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardiology 2003; 100:7-10.
23. Hamdy NM. Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 2011; 17: CR174-CR179.
24. Duman D, Palit F, Simsek E., Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008; 10:556-559.
25. Turk HM, Pekdemir H, Buyukberber S., et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003; 24:172-175.
26. Kosar F, Aksoy Y, Ozguntekin G., et al. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006; 8:270-274.
27. Varol E, Ozaydin M, Altinbas A., et al. Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 2007; 22:30-33.
28. Vizzardi E, D'Aloia A, Pezzali N, et al Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 2012; 18:68-73.
29. Hung CL, Hung TC, Liu C.C., et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 2012; 110:993-1000.
30. Ordu S, Ozhan H, Alemdar R., et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 2012; 39:30-35.
31. Nunez J, Nunez E, Sanchis J., et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 2011; 159:21-28.
32. Topalak O, Saygili U, Soyturk M., et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002; 85:108-113.
33. Cimbollek SH, Gonzalez-Quevedo T, Diaz FernandezM. CA 125: marker of serosal inflammation in hereditary angioedema? Allergy 2005; 60:835-836.
34. Molina R, Bosch X, Auge J.M., et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol 2012; 33:463-474.